StudyFinder
Site for ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Recruiting
We are continuing to study the SARS-CoV-2 coronavirus and the evolving new variants. We are looking at drugs that have Food and Drug Administration (FDA) approval for other uses. The goal is to determine if these drugs can make participants who get the coronavirus feel better faster and reduce death and hospitalizations.
Male or Female
18 years and over
Inclusion Criteria:
• at least 30 years old
• confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction (PCR) or antigen test collected within 10 days before starting study
• two or more current symptoms of acute infection for no more than 7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell
Exclusion Criteria:
• current or recent (within 10 days of starting study) hospitalization for COVID-19 infection
• current or planned participation in another interventional trial to treat COVID-19 (study physician will review)
• current or recent use (within the last 14 days) of study drug or study drug/device combination
Drug: Fluticasone, Drug: Fluvoxamine, Drug: Ivermectin, Drug: Metformin, Drug: Montelukast, Other: Placebo
COVID-19, Infectious Diseases
Primary Care, COVID, COVID-19
Covid Out - covidout@umn.edu
Carolyn Bramante
Phase 3
SITE00001271
See this study on ClinicalTrials.gov